Dr. Kim is a Senior Medical Director and the Clinical Development Team Lead for valoctocogene roxaparvovec (BMN 270). He joined BioMarin in June 2017 after serving as an Associate Medical Director at Roche, where he was the medical monitor for the HAVEN 1 (emicizumab) study.
Dr. Kim previously was an assistant professor at the University of California, San Francisco, where he cared for adolescent and adult persons with hemophilia in the hemophilia treatment center. In 2013, he received the Dr. Marion Koerper Award for Medical Excellence from the Hemophilia Foundation of Northern California. He completed his clinical training in hematology/oncology at the University of California, Los Angeles; earned a master’s degree in policy analysis at the Pardee RAND Graduate School; and finished his undergraduate, medical school, and internal medicine residency training at Northwestern University.